How is Moderna (MRNA) doing?
Moderna is a company in the biotechnology industry, based in Cambridge, MA, worth $89.3B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.
Updated Oct 9, 2026
Weak
Moderna shares are up 706% over the past year, 597 points ahead of the S&P 500. Its type is Faith Trade. Among large US stocks and funds it ranks in the 100th percentile on market beat, the 97th on staying power and the 0th on business growth. It appears on 8 of our dashboards, including 1st on “Which companies invest the most in research?” and 2nd on “Who is beating its rivals?”.
Compare with PFE · JNJ · AZN · REGN · BIIB
Financials, earnings and news on Stox ›The past year
Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.
What kind of stock is it?
Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.
Faith Trade
Beating the market steadily with buyers in control, though its business growth trails most. The price is ahead of the numbers.
Faith Trade since Feb; Bottom Fished before that.
Also Faith Trade (62 in all): IQV · CRL · RVTY · ACHC · MRK · PFE
MRNA on our dashboards
Every question where Moderna appears, in the order of the home page, with its reading and place in that table. Select a question to open it with MRNA highlighted. Select a column to sort.
| Question | Reading | Place | Details |
|---|---|---|---|
| What moved today, and why? What’s leading | –Typical | 15 of 30 | Today +14.2% · × normal day 1.6× |
| What moved this week? What’s leading | –Typical | 4 of 60 | This week +18.4% · × normal week 0.8× · 1M +65% |
| Which stocks keep winning? Leading stocks | 8930 of 52 wks | 57 of 60 | vs S&P, 1Y +690 pts · Rank steadiness 97 · P3 score 21 |
| Who is beating its rivals? Leading stocks | 100Ahead | 2 of 60 | 3M +184 pts · 1Y +604 pts · Rivals PFE, JNJ, AZN, REGN |
| Which companies invest the most in research? Business quality | 100Heavy | 1 of 60 | R&D / revenue 129.1% · R&D a year $2.9B · R&D, 1Y −25% |
| Which companies have more cash than debt? Value | 96Net cash | 18 of 60 | Net cash $4.5B · % of value +6% |
| Which companies pay the most in stock? Dividends and buybacks | 98Heavy | 8 of 60 | % of revenue 15.7% · A year $349.0M |
| Where is money flowing in? Who’s buying and selling | 98Inflow | 9 of 60 | 30 days 92 · 5 days 86 · Net buying +26% |
Go deeper on Stox
MRNA’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.
How to read this page
How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.
Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.
Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.
Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.
Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.
For financial statements, earnings and news, see MRNA’s full profile on Stox.
This page is information, not investment advice. About our data and methods ›